Biotech News

VistaGen Therapeutics to Report Fiscal Year 2022 Third Quarter Financial Results on February 10, 2022

Vistagen Therapeutics, Inc. (VTGN)Vistagen Therapeutics, Inc.Earnings

VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (CNS) disorders, will host a conference call and webcast on Thursday, February 10, 2022 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report its financial results for its fiscal year 2022 third quarter ended December 31, 2021 and provide a review of recent accomplishments and anticipated upcoming milestones.

Event: VistaGen Therapeutics Fiscal Year 2022 Third Quarter Financial Results Conference Call and Webcast Date: Thursday, February 10, 2022 Time: 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) US Dial-in (Toll Free): 1-877-407-9716 TOLL/International Dial-in: 1-201-493-6779 Conference ID: 13726261 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1523673&tp_key=49008240c8

A live audio webcast of the conference call will also be available via the link provided above. Participants should access this webcast site 10 minutes before the start of the call. In addition, a telephone playback of the call will be available after approximately 8:00 p.m. Eastern Time on Thursday, February 10, 2022. To listen to the replay, call toll free 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally (toll). Please use the replay PIN13726261. An archived webcast will be available on VistaGen’s website following the call.

About VistaGen VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three CNS drug candidates has a differentiated profile and therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on Twitter, LinkedIn, and Facebook.

VistaGen Company Contacts

Media:

Mark McPartland Vice President, Corporate Development Phone: (650) 577-3606 Email: [email protected]

Christy Curran Sam Brown Inc. Phone: (615) 414-8668 Email: [email protected]

Investors:

Mark Flather Vice President, Investor Relations Phone: (650) 577-3617 Email: [email protected]

Related news

Vistagen Therapeutics, Inc.

Vistagen Therapeutics is a neuroscience company focused on intranasal therapies for anxiety, depression, and related psychiatric conditions. Its story is built around trying to create faster-acting or better-tolerated treatments in mental health.

Recent company news

Stock data

Close
0.28 USD
Market cap
22.98M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States